ION Breast Cancer Clinical Pathways - ION Solutions

More documents

Recommendations

Info

Paraplatin (Carboplatin) VP-16 (Etoposide) EP=Moderate; FN=10%-20%Carboplatin AUC 5-6 D1Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 17:3540-3545, 1999Platinol (Cisplatin) Camptosar (Irinotecan) EP=High; FN=10%-20%Cisplatin 60mg/m 2 D1Irinotecan 60mg/m 2 D1, D8, D15q 28 Day CycleORCisplatin 30mg/m 2 D1, D8Irinotecan 65mg/m 2 D1, D8q 21 Day Cycle>> N Engl J Med 346:85-91, 2002>> J Clin Oncol 24:2038-2043, 2006Taxol (Paclitaxel) EP=Low, FN=10%-20%Paclitaxel 175mg/m 2 D1 (or weekly equivalent)q 21 Day Cycle>> Br J Cancer 77:347-351, 1998>> Anticancer Res 26:777-781, 2006Taxotere (Docetaxel) EP=Low; FN=10%-20%Docetaxel 100mg/m 2 D1 (or weekly equivalent)q 21 Day Cycle>> Eur J Cancer 30A:1058-1060, 1994Camptosar (Irinotecan) EP=Moderate; FN> J Clin Oncol 10:1225-1229, 1992Hycamtin (Topotecan) EP=Low; FN˃20%Topotecan 2.3mg/m 2 PO D1-5ORTopotecan 1.5mg/m 2 D1-5q 21 Day CycleORTopotecan 4mg/m 2 D1, D8, D15q 28 Day Cycle>> J Clin Oncol 17:658-667, 1999>> J Clin Oncol 24:5441-5447, 2006>> J Clin Oncol 25:2086-2092, 2007Gemzar (Gemcitabine) EP=Low; FN> J Clin Oncol 21:1550-1555, 2003>> Ann Oncol 12:557-561, 2001Page 34 of 39© 2013 by ION Solutions. All rights reserved
VP-16 (Etoposide) EP=Low; FN=10%-20%Etoposide 50mg/m2 PO D1-21q 28 Day Cycle>> J Clin Onc 8:1613-1617,1990Clinical Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Page 35 of 39© 2013 by ION Solutions. All rights reserved
Page 1 and 2: ION SolutionsNational Physician Net
Page 3: Best Supportive Care and/or Hospice
Page 6 and 7: Chemotherapy:Taxotere (Docetaxel) A
Page 8 and 9: Taxotere (Docetaxel) Paraplatin (Ca
Page 10 and 11: Taxotere (Docetaxel) EP=Low; FN=10%
Page 12 and 13: Herceptin (Trastuzumab) Followed by
Page 14 and 15: Herceptin (Trastuzumab) Taxotere (D
Page 16 and 17: Colon: First Line MetastaticChemoth
Page 18 and 19: 5-FU (5-Fluorouracil) Leucovorin +/
Page 20 and 21: Note: Wild Type KRAS documentation
Page 22 and 23: Camptosar (Irinotecan) Avastin (Bev
Page 24 and 25: Adjuvant Non-Small Cell Lung (NSCL)
Page 26 and 27: Paraplatin (Carboplatin) Taxotere (
Page 28 and 29: Best Supportive Care and/or Hospice
Page 30 and 31: Clinical Trial:Screen patient for c
Page 32 and 33: Small Cell Lung: Extensive Disease
Page 36 and 37: Anti-EmeticsEmetogenic Risk:High Em
Page 38 and 39: Lung CancerPage 38 of 39© 2013 by

ION Breast Cancer Clinical Pathways - ION Solutions

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?